Sio is returning the rights to the Parkinson's lentiviral gene therapy program, AXO-Lenti-PD, to Oxford Biomedica. Axovant licensed the global rights ...
https://www.google.com/url?rct=j&sa=t&url=https://www.fiercebiotech.com/biotech/as-ceo-goes-cash-woes-drive-sio-to-give-parkison-s-program-heave-ho&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNHppWU-94zIuyY8XGiqUZDoM_NCiA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.